Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated CLL

PURPOSE: Although rituximab-based chemoimmunotherapy (CIT) has substantially improved clinical outcomes in chronic lymphocytic leukemia (CLL), only 40-50% of patients achieve a complete remission (CR). There remains interest in identifying new approaches to improve the effectiveness of CIT. Ofatumum...

Full description

Saved in:
Bibliographic Details
Main Authors: Shanafelt, Tait, Lanasa, Mark C., Call, Timothy G, Beaven, Anne W., Leis, Jose F., LaPlant, Betsy, Bowen, Deborah, Conte, Michael, Jelinek, Diane F., Hanson, Curtis A., Kay, Neil E., Zent, Clive S.
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3894149/
https://ncbi.nlm.nih.gov/pubmed/23922059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28292
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items